COST-CONSEQUENCE OF CLADRIBINE TABLETS FOR THE TREATMENT OF HIGHLY-ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) IN THE UK

被引：0

作者：

Miller, B. ^{[1
]}

Russel-Szymczyk, M. ^{[2
]}

Jensen, I. S. ^{[3
]}

Shah, A. ^{[1
]}

Alexopoulos, S. T. ^{[4
]}

Herbert, A. ^{[4
]}

McLean, T. ^{[4
]}

Tundia, N. ^{[5
]}

机构：

[1] Precis Hlth Econ & Outcomes Res, Grafton, MA USA

[2] Merck Sp Zoo, Affiliate Merck KGaA, Warsaw, Poland

[3] Precis Hlth Econ & Outcomes Res, Boston, MA USA

[4] Merck Serono Ltd, Affiliate Merck KGaA, Feltham, England

[5] EMD Serono Res & Dev Inst Inc, Affiliate Merck KGaA, Billerica, MA USA

来源：

VALUE IN HEALTH | 2023年 / 26卷 / 12期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

EE658

引用

页码：S180 / S180

页数：1

共 50 条

[31] Cladribine tablets. Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods [J].

Meuth, S. G. ;

Ruck, T. ;

Aktas, O. ;

Hartung, H-P .

NERVENARZT, 2018, 89 (08) :895-907

[32] Cladribine tablets in relapsing-remitting multiple sclerosis preferentially target B-cells [J].

Ammoscato, Francesca ;

Wafa, Mohammad ;

Skonieczna, Justyna ;

Bestwick, Jonathan ;

Monero, Rosemary ;

Andrews, Michael ;

De Trane, Stefania ;

Holden, David ;

Adams, Ashok ;

Bianchi, Lucia ;

Turner, Ben ;

Marta, Monica ;

Schmierer, Klaus ;

Baker, David ;

Giovannoni, Gavin ;

Gnanapavan, Sharmilee .

CLINICAL IMMUNOLOGY, 2024, 269

[33] Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England [J].

Hettle, Robert ;

Harty, Gerard ;

Wong, Schiffon L. .

JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (07) :676-686

[34] Efficacy of alemtuzumab in relapsing-remitting multiple sclerosis (RRMS) patients with highly active disease despite therapy [J].

Confavreux, C. ;

Twyman, C. L. ;

Arnold, D. ;

Cohen, J. ;

Coles, A. J. ;

Fox, E. J. ;

Hartung, H-P. ;

Havrdova, E. ;

Selmaj, K. ;

Weiner, H. ;

Miller, T. ;

Lake, S. L. ;

Margolin, D. H. ;

Panzara, M. ;

Compston, A. .

EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 :88-88

[35] Subcutaneously delivered natalizumab for the treatment of highly active relapsing-remitting multiple sclerosis [J].

Haluskova, S. ;

Valis, M. .

CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2022, 85 (03) :206-212

[36] Effects of Cladribine Tablets on Circulating Lymphocyte Subset Reconstitution in the 96-Week CLARITY Study in Relapsing-Remitting Multiple Sclerosis (RRMS) [J].

Soelberg, Per ;

Rieckmann, Peter ;

comi, Giancarlo ;

Cook, Stuart ;

Giovannoni, Gavin ;

Rammohan, Kottil ;

Vermersch, Patrick ;

Bock, Daena ;

Hamlett, Anthony ;

Fevr, Tea ;

Musch, Bruno ;

Greenberg, Steve .

NEUROLOGY, 2010, 74 (09) :A372-A372

[37] Cost-effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain [J].

Ginestal, Ricardo ;

Rubio-Terres, Carlos ;

Moran, Olga Duran ;

Rubio-Rodriguez, Dario ;

De Los Santos, Heidi ;

Ordonez, Cristina ;

Sanchez-Magro, Isabel .

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (02)

[38] A simple mathematical model for relapsing-remitting multiple sclerosis (RRMS) [J].

Elettreby, M. F. ;

Ahmed, E. .

MEDICAL HYPOTHESES, 2020, 135

[39] Cerebellar information processing in relapsing-remitting multiple sclerosis (RRMS) [J].

Lesage, E. ;

Apps, M. A. J. ;

Hayter, A. L. ;

Beckmann, C. F. ;

Barnes, D. ;

Langdon, D. W. ;

Ramnani, N. .

BEHAVIOURAL NEUROLOGY, 2010, 23 (1-2) :39-49

[40] COST-EFFECTIVENESS OF CLADRIBINE TABLETS AND DIMETHYL FUMARATE IN THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS IN SPAIN [J].

Ginestal, R. ;

Duran, O. ;

Rubio Terres, C. ;

Rubio-Rodriguez, D. ;

De Los Santos, H. ;

Ordonez, C. ;

Sanchez, I .

VALUE IN HEALTH, 2022, 25 (12) :S82-S82

← 1 2 3 4 5 →